Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $2.3452W HIGH $6.30
Volume
429.53 K
Value Traded
1.06 M
Short % Float
10.11%
Days to Cover
3.7
-16.16%Week
-26.76%1 Month
-4.6%3 Month
-31.4%6 Month
-99.07%5 Year
-99.55%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
38.69 M
EPS (TTM)
0.44
P/E Ratio
5.69
Ent. Value
29.06 M
Total Shares
15.54 M
Float Shares
12.82 M
Insiders
17.53%
Institutions
17.07%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|
PoA blends historical approval base rates, trial design score and FDA review track record.
HYPD Catalyst Timeline
Dated clinical, regulatory and corporate events for Hyperion DeFi, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Hyperion DeFi, Inc.
352Total events
7Upcoming
108Tier-1 (high impact)
2018 to 2027Coverage
Upcoming catalysts 2
Event history 50
▲Quarterly UpdateCorporate
Hyperion DeFi repurchases 240,124 HYPD shares and retires ~$8.6M legacy debt
▲Debt Royalty FinancingCorporate
Hyperion DeFi retires legacy debt of approximately $8.6 million under Avenue Capital loan agreement
▲Equity OfferingCorporate
Hyperion DeFi repurchases 240,124 HYPD common shares at weighted average price of $3.21
●Quarterly UpdateCorporate
Hyperion DeFi reports 15,442,482 outstanding common shares, $14.5 million cash and 1.85 million Gross HYPE tokens as of September 30, 2026
▲Partnership / LicenseCorporate
Hyperion DeFi named launch partner for D3's Frontier Hyperliquid Vault
▲Partnership / LicenseCorporate
Hyperion DeFi supports DoubleZero Edge in launching Hyperliquid data feeds
▲Product LaunchPost-Market
DoubleZero Edge launches Hyperliquid data feeds with four feeds available at launch
▲Quarterly UpdateCorporate
Hyperion DeFi reports Q2 2026 financial results with record net income
▲Partnership / LicenseCorporate
Announcing new HAUS agreement with Entropy, an upcoming HIP-3 Deployer
▲Quarterly UpdateCorporate
Over 40,000 unique users signed up to Skew's private beta as of August 10, 2026
▲AcquisitionCorporate
Sale of remaining legacy Life Sciences IP to Arctic Vision executed in July 2026
▲Quarterly UpdateCorporate
Adjusted Net Operating Cash Flow expected to turn positive in Q3'26
▲Runway Guidance UpdateCorporate
Additional Q3'26 guidance provided (Adjusted Gross Profit $2.00M-$2.50M; Core Operating Earnings $0.00M-$0.50M; Adjusted Net Operating Cash Flow ($0.50M)-$0.25M)
▲Quarterly UpdateCorporate
1 million HYPE tokens redeployed to support HIP-3 & HIP-4 markets since June 2026
◆Partnership / LicenseCorporate
Executed LOI to monetize Optejet, potential closing in Q2 2026
◆Management ChangeCorporate
Robert Rubenstein to join as General Counsel effective January 12, 2026
▲Partnership / LicenseCorporate
Entered into HYPE Asset Use Service Agreement with Silhouette AG
▲Runway Guidance UpdateCorporate
FY'26 Adjusted Gross Profit guidance raised to $7M-$8M from $5M-$7M
▲Quarterly UpdateCorporate
Q3 2025 financial results reported with record net income of $6.6 million
▲Quarterly UpdateCorporate
13 million HYPE tokens staked to Hyperion's validator as of October 31, 2025
▲Partnership / LicenseCorporate
Strategic partnership with Felix to launch HIP-3 powered perpetual futures market
◆Timing GuidanceOptejetFiledPresentation
Eyenovia on track to file for U.S. regulatory approval of user-filled Optejet in Q4 2025
topical ophthalmic liquids (user-filled)source ↗
◆FDA Filing AcceptedOptejetFiledRegulatory Filing
Optejet UFD U.S. device regulatory approval submission
◆FDA Feedback ReceivedFDA Meeting
FDA registration of Optejet UFD on track for September 2025
topical ophthalmic liquidssource ↗
▼Equity OfferingCorporate
$50 million financing and establishment of treasury strategy in June 2025
Past FDA Catalysts and PDUFA Decisions
How HYPD actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| No matching catalysts | ||||||
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Valuation Signal
1
Drugs Scored
rNPV / MCap
Top Drug
Top 90%
Micro Cap(rank 601 of 668)
Percentile Rank
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Nebivolol 1 Percent Small MoleculesCompletedNCT04910100 | Open-Angle Glaucoma | Phase 2 | COMPLETED | 226 | Apr 29, 2022 |
Clinical Trial Results
Readouts, endpoints and source filings for every HYPD program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| low-dose atropine | pediatric progressive myopia | Phase 3 | 2024-11-15 | The rate of myopia progression was not significantly different between the two active treatment arms (0.01% and 0.1% atropine ophthalmic metered spray) and placebo.Read More | Eyenovia Provides Update on Phase 3 CHAPERONE Study A review of study data by an independent Data Review Committee found that CHAPERONE is not meeting its primary three-year efficacy endpoint Company to discontinue studyRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Walters Happy DavidDirector | Grant/Award | 58,917 170,847 held | $0.00 | 06/30/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in HYPD
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in HYPD for Q2 2026. | ||||
Ownership Trends
HYPD Short Interest
Shares sold short, counted twice a month.
10.11%
Short % of Float
of tradable shares sold short
1.3M
Shares Sold Short
+14.6% vs prior count
3.7 Moderate
Days to Cover
trading days of normal volume to buy every short share back
348.9K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How HYPD ranks across every disease it competes in
Competitive Position is a premium feature
See how HYPD ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialHYPD News
HYPDHyperion DeFi Schedules Third Quarter Earnings Call for Thursday, November 12 at 8:00 a.m. ET
Hyperion DeFi, Inc. has announced its third quarter earnings call scheduled for November 12, 2026. The call will provide insights into the company's performance for the quarter ending September 30, 2026. Participants can join via dial-in or webcast, and a press release with results will be issued prior to the call.
Read more →HYPDHyperion DeFi Commences Share Buybacks, Retires All Legacy Debt, and Commits to Further Capital Optimization
Hyperion DeFi, Inc. has initiated a share buyback of 240,124 shares at $3.21 each and has fully retired its legacy debt of approximately $8.6 million. This move is part of the company's strategy to optimize its capital structure and enhance flexibility for scaling its onchain DeFi businesses. CEO Hyunsu Jung highlighted the positive developments in September, including raised guidance and new business announcements.
Read more →HYPD▼ -6.1%on this newsshared move
Hyperion DeFi, Anchorage Digital, and HyperLend Together Announce the First Institutional Credit Facility on Hyperliquid
Hyperion DeFi, Inc. has launched the first institutional credit facility on HyperLend's Aviya Finance platform, utilizing Anchorage Digital's regulated infrastructure. This facility allows institutions to access onchain credit while securing obligations with staked HYPE tokens. The initiative aims to enhance liquidity for real-world assets and expand institutional participation in the Hyperliquid ecosystem.
Read more →HYPDHyperion DeFi Supports D3’s Frontier Vault Launch, Bringing Internet Domain Priority Access to the Hyperliquid Ecosystem
Hyperion DeFi has partnered with D3 to launch the Frontier Vault, providing priority access to new internet top-level domains (TLDs). This initiative comes as ICANN opens its second application round for TLDs, with over 1,600 applications submitted. The partnership aims to integrate domains as real-world assets into the DeFi ecosystem, potentially transforming how domains are utilized.
Read more →HYPD▲ +10.9%on this newsshared move
Hyperion DeFi Supports DoubleZero Edge in Launching the Fastest Commercially Available Hyperliquid Data Feeds
Hyperion DeFi has partnered with DoubleZero Edge to launch high-speed Hyperliquid data feeds, enhancing its blockchain ecosystem. This initiative marks Hyperion's first collaboration with an external team, aiming to support market participants in onchain finance. Subscribers will benefit from direct access to various trading venues without intermediaries, with plans for future expansion.
Read more →HYPD▲ +8.5%on this news
Hyperion DeFi Raises Guidance and Announces $20M Share Repurchase Program
Hyperion DeFi, Inc. has raised its full-year 2026 guidance, anticipating an Adjusted Gross Profit of $7M-$8M, up from $5M-$7M. The company expects to achieve positive Adjusted Net Operating Cash Flow and Core Operating Earnings in Q3 2026. Additionally, Hyperion has announced a $20 million share buyback program to enhance shareholder value.
Read more →HYPD▲ +5.2%on this news
Hyperion DeFi Reports 2Q 2026 Financial Results with Another Record Quarterly Net Income and Strong Operating Momentum
Hyperion DeFi, Inc. reported a record net income of $31.0 million for Q2 2026, marking a significant increase from the previous quarter. The company's Adjusted EBITDA also rose to $53.7 million, reflecting strong operational momentum. Hyperion announced new partnerships with Entropy and Skew, aimed at enhancing its DeFi offerings. Additionally, the company successfully reduced its operating expenses by 46% compared to the previous year.
Read more →HYPDHyperion DeFi Schedules First Quarter Earnings Call for Wednesday, August 12 at 5:00 p.m. ET
Hyperion DeFi, Inc. has announced its earnings conference call for the second quarter ending June 30, 2026, scheduled for August 12, 2026, at 5:00 p.m. ET. The call will provide insights into the company's performance and future prospects. A press release detailing financial results will be issued prior to the call.
Read more →HYPDHyperion DeFi Schedules Second Quarter Earnings Call for Wednesday, August 12 at 5:00 p.m. ET
Hyperion DeFi, Inc. has announced its second quarter earnings call scheduled for August 12, 2026. The call will provide insights into the company's financial performance for the quarter ending June 30, 2026. A press release with detailed results will be issued prior to the call. Hyperion DeFi is recognized as the first U.S. publicly listed DeFi company.
Read more →HYPDHyperion DeFi Enters Agreement with Skew Technologies to Launch HIP-3 Perpetual Futures Market and Listing Service
Hyperion DeFi has entered a partnership with Skew Technologies to deploy 500,000 HYPE tokens for a new suite of institutional perpetual futures products on Hyperliquid's HIP-3 markets. This agreement allows for the launch of custom markets and provides Hyperion with equity participation and revenue sharing. The collaboration aims to enhance market operations and expand trading product offerings.
Read more →HYPD▲ +7.5%on this news
Hyperion DeFi and Blockdaemon Partner to Expand Institutional Hyperliquid Staking Infrastructure
Hyperion DeFi has partnered with Blockdaemon to enhance its staking infrastructure for institutional clients on the Hyperliquid platform. This collaboration aims to meet the growing demand for reliable validator services and support institutional participation in decentralized finance. The partnership is a significant step towards scaling Hyperion's offerings and expanding its presence in the DeFi ecosystem.
Read more →HYPDHyperion DeFi Reiterates Guidance on Sunset of USDH and Felix Markets
Hyperion DeFi has reiterated its full-year guidance of $5 million to $7 million Adjusted Gross Profit despite the sunset of USDH and Felix Markets. The company plans to redeploy its HYPE tokens into more profitable strategies. CEO Hyunsu Jung emphasized the ongoing demand for their services and the commitment to innovation in the DeFi space.
Read more →HYPDHyperion DeFi Reports 1Q 2026 Financial Results with Record Net Income and Raises Guidance for Full Year 2026
Hyperion DeFi reported robust financial results for Q1 2026, achieving a record net income of $8.8 million and an adjusted EBITDA of $19.5 million. The company's strategic 'Triple-Dip' deployment of HYPE tokens resulted in more than triple the income relative to traditional staking. CEO Hyunsu Jung emphasized the expanding opportunities presented by Hyperliquid and announced an increase in guidance for the full year 2026, as the company aims for break-even cash flows by year's end.
Read more →HYPDHyperion DeFi Announces Closing of Public Offering of Common Stock
Hyperion DeFi, Inc. has successfully closed a public offering of 2,777,778 shares of common stock, raising approximately $10 million. The shares were sold at $3.60 each, with the proceeds aimed at funding the company's HYPE treasury strategy and general corporate needs. The offering was underwritten by Chardan and supported by prominent investors.
Read more →HYPD▼ -22.1%on this newsshared move
Hyperion DeFi Announces Pricing of Public Offering of Common Stock
Hyperion DeFi, Inc. has announced the pricing of a public offering of 2,777,778 shares of common stock at $3.60 per share, aiming to raise around $10 million. The offering is set to close on May 7, 2026, pending customary conditions. Proceeds will be used for funding its treasury strategy and general corporate purposes.
Read more →HYPDHyperion DeFi Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
Hyperion DeFi, Inc. has announced a proposed public offering of common stock and pre-funded warrants. The offering is subject to market conditions and aims to fund its treasury strategy and general corporate purposes. Chardan is acting as the sole underwriter, and there are no assurances regarding the timing or size of the offering.
Read more →HYPDHyperion DeFi Schedules First Quarter Earnings Call for Thursday, May 14 at 8:00 a.m. ET
Hyperion DeFi, Inc. has scheduled its first quarter earnings call for May 14, 2026, at 8:00 a.m. ET. The call will provide insights into the company's financial performance for the quarter ending March 31, 2026. A press release with detailed results will be issued prior to the call. Hyperion DeFi is recognized as the first publicly listed DeFi company in the U.S.
Read more →HYPD▲ +5.3%on this news
Hyperion DeFi Announces Participation in Upcoming Investor and Industry Conferences
Hyperion DeFi, Inc. announced its participation in several upcoming conferences, including the Digital Asset Yield Summit and Consensus Miami. The company aims to engage with investors and showcase its developments in the DeFi space. Additionally, Hyperion is working on the Optejet User Filled Device, enhancing treatment compliance for eye diseases.
Read more →HYPD▼ -5.7%on this news
Hyperion DeFi Reports 4Q and FY 2025 Financial Results with Quarter-over-Quarter Growth of +64% Revenue and +87% Adjusted Gross Profit
Hyperion DeFi, Inc. reported strong financial results for Q4 and FY 2025, with a 64% increase in revenue and an 87% rise in adjusted gross profit. The company's innovative 'Triple-Dip' strategy significantly boosted staking income. Despite these gains, Hyperion faced a net loss of $39.8 million in Q4 2025, highlighting ongoing challenges in the volatile market.
Read more →HYPDHyperion DeFi Enters HAUS Agreement with Silhouette
Hyperion DeFi has entered a HYPE Asset Use Service agreement with Silhouette, allowing users to benefit from reduced transaction fees on the Hyperliquid platform. This partnership aims to enhance trading efficiency while maintaining user privacy. Silhouette's architecture enables sophisticated trading strategies without compromising on execution. The collaboration is expected to drive growth and attract more users to the ecosystem.
Read more →About Hyperion DeFi, Inc.
Headquarters3090 NOWITZKI WAY, DALLAS, TX, 75219
BIOPHARMAWATCH ELITE PLUS
Trade the next HYPD catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime